{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:11:59Z","timestamp":1793261519897,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008732","name":"Uehara Memorial Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["RE\/18\/6\/34217"],"award-info":[{"award-number":["RE\/18\/6\/34217"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-cardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jjcc.2023.11.005","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T14:03:33Z","timestamp":1700661813000},"page":"133-140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Relevant adverse events and drug discontinuation of sacubitril\/valsartan in a real-world Japanese cohort: REVIEW-HF registry"],"prefix":"10.1016","volume":"84","author":[{"given":"Shingo","family":"Matsumoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahito","family":"Nasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Kagiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Kida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Ijichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuhiro","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshiro","family":"Kanaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jjcc.2023.11.005_bb0005","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2023.11.005_bb0010","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2023.11.005_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2023.04.019","article-title":"Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure","volume":"82","author":"Mentz","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2023.11.005_bb0020","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1093\/eurheartj\/ehad344","article-title":"Sacubitril\/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF","volume":"44","author":"Vaduganathan","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2023.11.005_bb0025","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2023.11.005_bb0030","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1001\/jamacardio.2021.4567","article-title":"Effect of treatment with sacubitril\/valsartan in patients with advanced heart failure and reduced ejection fraction","volume":"7","author":"Mann","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jjcc.2023.11.005_bb0035","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2023.11.005_bb0040","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2023.11.005_bb0045","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.cardfail.2021.04.023","article-title":"JCS\/JHFS 2021 guideline focused update on diagnosis and treatment of acute and chronic heart failure","volume":"27","author":"Tsutsui","year":"2021","journal-title":"J Card Fail"},{"key":"10.1016\/j.jjcc.2023.11.005_bb0050","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.jacc.2015.03.043","article-title":"Patient selection in heart failure with preserved ejection fraction clinical trials","volume":"65","author":"Kelly","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2023.11.005_bb0055","doi-asserted-by":"crossref","first-page":"193","DOI":"10.36628\/ijhf.2022.0015","article-title":"Real-world usage of sacubitril\/valsartan in Korea: a multi-center, retrospective study","volume":"4","author":"Park","year":"2022","journal-title":"Int J Heart Fail"},{"key":"10.1016\/j.jjcc.2023.11.005_bb0060","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1002\/ehf2.14097","article-title":"Sacubitril\/valsartan in heart failure: efficacy and safety in and outside clinical trials","volume":"9","author":"Abdin","year":"2022","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jjcc.2023.11.005_bb0065","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/ehf2.12251","article-title":"Eligibility of sacubitril-valsartan in a real-world heart failure population: a community-based single-centre study","volume":"5","author":"Norberg","year":"2018","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jjcc.2023.11.005_bb0070","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/ejhf.1465","article-title":"Real-world treatment patterns of sacubitril\/valsartan: a longitudinal cohort study in Germany","volume":"21","author":"Wachter","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jjcc.2023.11.005_bb0075","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/ejhf.580","article-title":"Efficacy of sacubitril\/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial","volume":"18","author":"Vardeny","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jjcc.2023.11.005_bb0080","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4070\/kcj.2019.0136","article-title":"Sacubitril\/valsartan in Asian patients with heart failure with reduced ejection fraction","volume":"49","author":"Dewan","year":"2019","journal-title":"Korean Circ J"},{"key":"10.1016\/j.jjcc.2023.11.005_bb0085","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1253\/circrep.CR-21-0068","article-title":"Initial real-world practical experience of sacubitril\/valsartan treatment in Japanese patients with chronic heart failure","volume":"3","author":"Nakamura","year":"2021","journal-title":"Circ Rep"},{"key":"10.1016\/j.jjcc.2023.11.005_bb0090","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.cardfail.2022.09.018","article-title":"Epidemiology, pathophysiology, diagnosis, and therapy of heart failure with preserved ejection fraction in Japan","volume":"29","author":"Obokata","year":"2023","journal-title":"J Card Fail"},{"key":"10.1016\/j.jjcc.2023.11.005_bb0095","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/ejhf.2076","article-title":"OUTSTEP-HF: randomised controlled trial comparing short-term effects of sacubitril\/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction","volume":"23","author":"Piepoli","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jjcc.2023.11.005_bb0100","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/ejhf.1498","article-title":"Initiation of sacubitril\/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study","volume":"21","author":"Wachter","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jjcc.2023.11.005_bb0105","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1002\/ehf2.12883","article-title":"Implementation of sacubitril\/valsartan in Sweden: clinical characteristics, titration patterns, and determinants","volume":"7","author":"Fu","year":"2020","journal-title":"ESC Heart Fail"}],"container-title":["Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508723002769?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508723002769?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T04:34:01Z","timestamp":1762317241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0914508723002769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0914508723002769"],"URL":"https:\/\/doi.org\/10.1016\/j.jjcc.2023.11.005","relation":{},"ISSN":["0914-5087"],"issn-type":[{"value":"0914-5087","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relevant adverse events and drug discontinuation of sacubitril\/valsartan in a real-world Japanese cohort: REVIEW-HF registry","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jjcc.2023.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Japanese College of Cardiology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}